This retrospective research aimed to study the prescribing trends of antibiotics for influenza and adherence to the guidelines issued by the Infectious Diseases Society of America (IDSA) by utilizing the National Ambulatory Medical Survey (NAMCS) 2016 database. This was based on a sample of visits to non-federally employed officebased physicians who are engaged in direct patient care at community health centers. Patient sex, race, as well as the source of payment, and the provider type were among the demographic variables studied for adherence to the guidelines. The total number of ambulatory care visits were 1,753. Of those, 63.6% of patients were prescribed, inappropriate agents. General and Family Practice physicians were the most frequented providers (32.9%), followed by Nurse Practitioners (21.9%), and Pediatricians (17.1%). Family practice physicians and nurse practitioners appeared to prescribe more inappropriately as compared to the other specialties (X2 =0.001). White and black patients were prescribed more inappropriately as compared to other races (X2 =0.032). Antibiotic resistance is a public health problem of increasing magnitude, and finding effective solutions to address this problem is critical. Antibiotic resistance is also an economic healthcare burden. Adherence to guidelines minimizes antibiotic resistance and promotes patients and public health.

Acute Diarrhea (AD) is a highly prevalent condition that causes significant morbidity and mortality worldwide. Conventional therapies include Oral Rehydration Solutions (ORS), Antibiotics, and Zinc Products. Emerging data suggest that Probiotics use in the treatment and control of AD cases in children may help supplement current therapies for further control. Herein, we review the evidence of several Probiotics modalities for AD treatment. We describe the Clinical Impact and prevalence of Acute Diarrhea in children and its complications, provide an overview of current treatments, and finally, discuss recent emergent Gut approaches to AD management. Specifically, we will describe in a Comparative study on the utility of different kinds of Probiotics known and used and common natural products in the treatment of Acute cases of AD and focus on recent, high-quality studies. Adverse effects and potential interactions of each therapy will be highlighted where applicable.

The number of patients with T2DM is progressively increasing all over the world, and one of the most severe chronic complications of diabetes is the development of Cardiovascular Disease (CVD). The burden of diabetes is now a huge Palestinian public health challenge increase substantially in the next two decades. The aim of the study to investigate the relationship between plasma Galactin-3 and NT-BNP level with the development of CVD in T2DM in Palestinian patients. Case-control study design, this study was conducted in the laboratory of Central laboratory in Remal Clinic, Gaza Strip-Palestine in the period from July to October 2018, included 180 subjects divided to the three groups control, T2DM patients and T2DM with CVD, 60 individual in each group, matching for age. Vacutainer serum and EDTA blood samples were collected from all participants for the laboratory analysis. These results showed that there were highly significant differences (P>0.01) in serum Galectin-3 level in the T2DM group compared with T2DM and CVD group, while NT-BNP results there was no significant difference between the T2DM group and T2DM with CVD group. Also, the study revealed that Galectin-3 was found to be more sensitive and specific by using Roc curve statistical test (sensitivity was 83.3%, specificity was 75.0%, p<0.01), than NT-BNP (sensitivity was 81.7%, specificity was 23.3% p>0.05) in predicting cardiovascular complications in T2DM patients We concluded that the Galectin-3 is the best novel biomarkers in comparison with NT-BNP that aid in the early diagnostic and prognostic evaluation either alone or in combination with other biomarkers for cardiovascular complications in a patient with T2DM.

Image article